title: Arachidonic acid metabolism and casein secretion in lactating rabbit mammary epithelial cells: effects of inhibitors of prostaglandins and leukotrienes synthesis.
abstract: The metabolism of arachidonic acid (AA) in fragments of lactating rabbit mammary glands in vitro was studied by considering the distribution of 13-[14C]AA in the cells, and the effects of inhibitors of cyclooxygenase and lipoxygenase pathway on the basal and prolactin (PRL)-stimulated casein secretion. 13-[14C]AA was incorporated in all classes of lipids and PRL increased transiently the percentage of free fatty acid after 1 and 5 min. Ten microM ETYA (5,8,11,14-Eicosatetraynoic acid), a tetrayne analogue of AA inhibited prostaglandins F2 alpha (PGF2 alpha) production but not leukotrienes B4 and C4 (LTB4 and LTC4) production and increased basal casein secretion. 10(-4) M DCHA (Docosahexaenoic acid) a competitive inhibitor of prostaglandin-synthetase inhibited PGF2 alpha production but did not affect basal nor PRL-stimulated casein secretion. Fourteen microM indomethacin inhibited PGF2 alpha and LTC4 production and PRL-stimulated casein secretion. Ten microM NdgA (nordihydroguaiaretic acid) an inhibitor of lipoxygenase pathway, inhibited LTB4 and LTC4 production, increased basal level of casein secretion and inhibited PRL-stimulated casein secretion. Hundred microM caffeic acid, an inhibitor of glutathione-S-transferase (GST), a class of enzymes implied in the transformation of LTA4 into LTC4, had the same effect that NDGA on basal and PRL-stimulated casein secretion. These findings show that inhibitors of AA metabolites alter casein secretion.
authors.affiliation: Laboratoire de Physiologie de la Lactation INRA-CRJ, Jouy-en-Josas, France.
authors.forename: F
authors.initials: F
authors.lastname: Blachier
authors.forename: M C
authors.initials: MC
authors.lastname: Lacroix
authors.forename: A M
authors.initials: AM
authors.lastname: Ahmed
authors.forename: C
authors.initials: C
authors.lastname: Léger
authors.forename: M
authors.initials: M
authors.lastname: Ollivier-Bousquet
mesh_terms: D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D002109:Caffeic Acids / Q000494:pharmacology; D002364:Caseins / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors; D015237:Dinoprost; D004281:Docosahexaenoic Acids / Q000494:pharmacology; D004848:Epithelium / Q000378:metabolism; D005260:Female; D005982:Glutathione Transferase / Q000037:antagonists & inhibitors; D007213:Indomethacin / Q000494:pharmacology; D007774:Lactation / Q000378:metabolism*; D007975:Leukotriene B4 / Q000096:biosynthesis; D016859:Lipoxygenase Inhibitors; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000378:metabolism*; D009637:Masoprocol / Q000494:pharmacology; D011247:Pregnancy; D011388:Prolactin / Q000494:pharmacology; D011460:Prostaglandins F / Q000096:biosynthesis; D011817:Rabbits; D013189:SRS-A / Q000096:biosynthesis
chemical_list: D001095:Arachidonic Acids; D002109:Caffeic Acids; D002364:Caseins; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D011460:Prostaglandins F; D013189:SRS-A; D015117:5,8,11,14-Eicosatetraynoic Acid; D007975:Leukotriene B4; D004281:Docosahexaenoic Acids; D016718:Arachidonic Acid; D009637:Masoprocol; D011388:Prolactin; D015237:Dinoprost; D005982:Glutathione Transferase; C040048:caffeic acid; D007213:Indomethacin